Table 1 Demographic characteristics, clinical symptoms and SARS-CoV-2 lineage data from a cohort of outpatient participants in Los Angeles County and Riverside County, California, May 27, 2021 to September 9, 2021 (n = 503).
From: Local monitoring of SARS-CoV-2 variants in two large California counties in 2021
Variable | Mean/number | Standard deviation or percent |
|---|---|---|
Age, years | 40.9 | 12.6 |
Gender, female | 238 | 47.3% |
Days to collection | 2.8 | 0.7 |
Ethnicity | ||
Not disclosed | 25 | 5.0% |
Black or African American | 1 | 0.2% |
Hispanic or Spanish origin | 221 | 43.9% |
Not Hispanic or Spanish origin | 208 | 41.4% |
Prefer not to share | 48 | 9.5% |
Vaccinated | ||
No | 182 | 36.2% |
Yes | 320 | 63.6% |
Declined to disclose | 1 | 0.2% |
Vaccine manufacturer | ||
J&J | 56 | 16.6% |
Moderna | 98 | 29.1% |
Pfizer | 179 | 53.1% |
Pfizer and AstraZeneca | 1 | 0.3% |
Sinopharm | 3 | 0.9% |
Symptoms | ||
Congestion or runny nose | 375 | 75.6% |
Cough | 368 | 74.2% |
Fatigue | 343 | 69.2% |
Headache | 301 | 60.7% |
Muscle or body aches | 290 | 58.5% |
New loss of taste or smell | 289 | 58.3% |
Fever or chills | 220 | 44.4% |
Sore throat | 216 | 43.5% |
Shortness of breath | 125 | 25.2% |
Diarrhea | 105 | 21.2% |
Nausea or vomiting | 80 | 16.1% |
Bleeding | 1 | 0.2% |
Eye redness or dry mouth | 1 | 0.2% |
Stomach pain | 1 | 0.2% |
